FENNEC PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
FENC$10.58-2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(U.S. dollars in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended | ||||||
| · · December 31, · · December 31, | ||||||
| | 2023 | 2022 | ||||
| | | | | | | |
| Cash flows (used in) provided by: · · | ||||||
| Operating activities: · · | ||||||
| Net loss | | $(16,045) | | $(23,714) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | |||
| Amortization of debt access fees | | 221 | | 132 | ||
| Amortization of debt discount | | | 66 | | | 17 |
| Unrealized loss on securities | | | 39 | | | 184 |
| Stock-based compensation - consultants | | — | | 133 | ||
| Stock-based compensation - employees | | 5,354 | | 4,087 | ||
| Changes in operating assets and liabilities: | | | | |||
| Accounts receivable, net | | | (7,269) | | | (1,545) |
| Prepaid expenses | | 104 | | 264 | ||
| Inventory | | | (1,580) | | | (576) |
| Other assets | | 3 | | 6 | ||
| Accounts payable | | 1,388 | | 1,612 | ||
| Accrued liabilities | | 576 | | 1,342 | ||
| Net cash used in operating activities | | (17,143) | | (18,058) | ||
| | | | ||||
| Financing activities: | | | ||||
| Issuance of shares, options exercise | | 1,716 | | 928 | ||
| Proceeds from long-term debt | | | 4,997 | | | 24,935 |
| Long term debt paid | | | — | | | (5,000) |
| Debt discount | | | 3 | | | 238 |
| Cash paid for taxes on restricted share release | | | (78) | | | (194) |
| Capitalized deferred issuance costs | | — | | (175) | ||
| Net cash provided by financing activities | | 6,638 | | 20,732 | ||
| | | | | | | |
| (Decrease)/increase in cash and cash equivalents | | | (10,505) | | | 2,674 |
| Cash and cash equivalents - Beginning of year | | | 23,774 | | | 21,100 |
| Cash and cash equivalents - End of year | | $13,269 | | $23,774 | ||
| | | | | | | |
| Non-cash investing and financing activities: | | | ||||
| Financed insurance policy | | $403 | | $550 | ||
| Warrants issued in connection with term loan | | $— | | $441 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.